Hold On Genetics Cancer Trial Lifted
Seattle Genetics’ cancer candidate drug talirine in acute myeloid leukemia was put on hold during early to mid stage trials by the FDA after death of four patients; however the FDA has lifted the clinical hold and two Phase 1 trials have resumed. One of the trials on hold is a study of vadastuximab talirine …